Magnesium and parathyroid hormone among end-stage renal disease patients

Seyed Seifollah Beladi Mousavi; Fatemeh Hayati; Shokouh Shayanpour; Shahla Ahmadi Halili

doi:10.15171/jpd.2018.22

J Parathyr Dis. 2018;6(2): 72-73.
doi: 10.15171/jpd.2018.22

Abstract View: 3615

PDF Download: 1194

Commentary

Magnesium and parathyroid hormone among end-stage renal disease patients

Seyed Seifollah Beladi Mousavi, Fatemeh Hayati, Shokouh Shayanpour, Shahla Ahmadi Halili^*

¹ Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

*Corresponding Author: *Corresponding author: Shahla Ahmadi Halili,, Email: Ahmadihalili@gmail.com

Abstract

Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.

Keywords: Magnesium, Parathyroid hormone, Chronic kidney disease, End-stage renal disease

First Name

Last Name

Email Address

Comments

Security code

Generate New Image

Type the code from the image

Abstract View: 3616

years	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2024	37	44	40	56	49	53	42	46	57	52	31	37
2023	45	38	63	49	6	51	61	50	56	50	50	29
2022	77	89	82	84	43	73	63	44	42	55	46	50
2021	57	49	61	61	65	67	58	61	73	97	51	57
2020	49	38	50	48	57	50	72	193	147	87	66	52
2019										9	58	43